Novo Nordisk's second largest investor, USA's Capital Group Companies (CGC), has since 2004 earned more than DKK 10 bn (USD 1.9 bn) on its shareholding in the Danish medico giant. CGC invested in Novo Nordisk for the first time in 2002, increased its stake to 5% in 2003, and to 10% in 2004. In 2006, the investment management company increased its share to 13%, and during 2007 made further investments to bring its current stake in Novo Nordisk to 15%.
Jesper Brandgaard, group financial director of Novo Nordisk, describes CGC as a large and significant shareholder which he believes is satisfied with its investment. Brandgaard says that the two parties have a lively dialogue regarding future strategic focus, and that CGC "has a lot of insight into our field of operation".
Simon Levell, spokesman of Capital Group Companies says: "I can't specifically tell you about our intentions with the investment in Novo Nordisk, but we are a long-term investment company which does not invest to gain control and we do not attempt to exert ill-timed influence on the management."
Novo Nordisk is a healthcare company and a world leader in diabetes care. It also has a leading position in haemostasis management, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs more than 23,600 people in 79 countries, and markets its products in 179 countries. Novo Nordisk’s B shares are listed on the stock exchanges in Copenhagen and London.
The news was reported by financial daily newspaper Børsen.